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a b s t r a c t
This paper summarizes results obtainedbymultiplexPCR screeningof humanclinical samples for respira-
tory viruses and corresponding data obtained after passaging of virus-positive samples inMDCK 33016PF
cells. Using the ResPlexII v2.0 (Qiagen) multiplex PCR, 393 positive results were obtained in 468 clinical
samples collected during an inﬂuenza season in Germany. The overall distribution of positive results
was inﬂuenza A 42.0%, inﬂuenza B 38.7%, adenovirus 1.5%, bocavirus 0.5%, coronavirus 3.3%, enterovirus
5.6%, metapneumovirus 1.0%, parainﬂuenza virus 0.8%, rhinovirus 4.1%, and respiratory syncytial virus
(RSV) 2.5%. Double infections of inﬂuenza virus together with another virus were found for adenovirus B
and E, bocavirus, coronavirus, enterovirus and for rhinovirus. These other viruses were rapidly lost upon
passages in MDCK 33016PF cells and under conditions as applied to inﬂuenza virus passaging. Clinical
samples, inwhich no inﬂuenza virus but other viruseswere found,were also subject to passages inMDCK
33016PF cells. Using lower inoculum dilutions than those normally applied for preparations containing
4inﬂuenza virus (total dilution of the original sample of ∼10 ), the positive results for the different viruses
turned negative already after 2 or 3 passages in MDCK 33016PF cells. These results demonstrate that,
under practical conditions as applied to grow inﬂuenza viruses, contaminating viruses can be effectively
removed by passages in MDCK cells. In combination with their superior isolation efﬁciency, MDCK cells
appear highly suitable to beused as an alternative to embryonated eggs to isolate andpropagate inﬂuenza
vaccine candidate viruses.. Introduction
Inﬂuenza virus isolation for monitoring epidemic inﬂuenza
ctivity and for the selection of candidate vaccine strains has tradi-
ionally been conducted by cultivation in embryonated hen’s eggs.
ue to receptor limitations, such egg passaging can cause adaptive
utations of the haemagglutinin [1,2]. These egg-adaptive muta-
ions do not revert on subsequent passage inmammalian cells, and
heymay alter the antigenic properties of the receptor binding site,
hich is also a critical binding site for virus inhibiting and protec-
ive antibodies [3,4]. In contrast to egg-passaged virus,mammalian
ell-grown inﬂuenza virus preserves the sequence of the original
uman clinical sample.
During the last decade the worldwide National Inﬂuenza Cen-res have almost completely changed inﬂuenza virus isolation from
gg culture to cell culture, mainly using MDCK cells. This change
o cell culture was stimulated not only by the relative ease of
∗ Corresponding author. Tel.: +49 06421 39 4064; fax: +49 06421 39 5159.
E-mail address: bernhard.roth@novartis.com (B. Roth).
264-410X/© 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.
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conducting multiple isolations in cell cultures but also by the bet-
ter antigenic match of MDCK-isolated viruses with ﬁeld strains.
Increasing difﬁculties in recovering isolates from embryonated
eggs, particularly of H3N2 subtypes, has also contributed to the
change to cell culture [5].
Several companies are currently developing cell culture-based
inﬂuenza vaccines [6] and the ﬁrst of those vaccines, produced
in MDCK and Vero cells, have been licensed and distributed as
interpandemic trivalent and pandemic H1N1 vaccines. Using the
conventional, recommended reference viruses, these vaccines still
originate from egg-derived virus isolates or the corresponding
high-growth reassortants. Regulatory concerns,mainlywith regard
to the introduction of adventitious agents, are raised if candi-
date vaccine strains are derived directly from uncharacterised and
uncontrolled cell lines. Collaborative studies have been initiated to
investigate the growth and yield of inﬂuenza viruses in different
cell lines, the efﬁciency and ﬁdelity of inﬂuenza virus isolation, and
the suitability for vaccine manufacture of different cell substrates
[7]. Growth studies with a wide range of potentially contaminat-
ing viruses have been conducted and risk assessments have been
made, comparing egg-derived and cell-passaged inﬂuenza viruses
5 cine 30 (2012) 517– 522
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Table 1
ResPlex II v2.0 multiplex PCR target pathogens and target genes.
Pathogen Targeted gene
Respiratory syncytial virus A Nonstructural protein (NS)
Respiratory  syncytial virus B Nonstructural protein (NS)
Inﬂuenza  virus A Nonstructural protein (NS)
Inﬂuenza  virus B Nonstructural protein (NS)
Parainﬂuenza  virus 1 Nucleocapsid protein (N)
Parainﬂuenza  virus 2 Nucleocapsid protein (N)
Parainﬂuenza  virus 3 Nucleocapsid protein (N)
Parainﬂuenza  virus 4 Nucleocapsid protein (N)
Human  metapneumovirus Fusion protein (F)
Rhinovirus 5′ UTR
Enterovirus (Coxsackie virus, Echovirus) 5′ UTR
Coronavirus OC43 Nucleocapsid protein (N)
Coronavirus  229E Nucleocapsid protein (N)
Coronavirus  NL63 Nucleocapsid protein (N)
Coronavirus  HKU1 Nucleocapsid phosphoprotein (N)
Bocavirus Nonstructural protein (NS)
Adenovirus  types 3, 7, and 21 Hexon18 B.  Roth et al. / Vac
ith regard to the risk of carrying adventitious viruses into vac-
ine manufacturing processes [8,9]. These assessments indicated
hat, in comparison to manufacturing in embryonated eggs, the
ntroduction of Vero cells increases the risk of transmitting var-
ous viruses into the vaccine process, whereas the use of MDCK
ells reduces the overall risk. Due to their limited permissiveness
o viral growth, MDCK cell exert the same ﬁlter effect for human
dventitious viruses as do embryonated eggs.
Here, we assess on the presence of co-isolated viruses in
nﬂuenza virus isolates recovered from MDCK cells. This article
rovides more speciﬁc data about the kind and frequency of co-
nfecting respiratory viruses in human inﬂuenza virus-containing
amples and about the fate of such co-infecting viruses during pas-
age in MDCK cells.
.  Materials and methods
.1.  Clinical material
Nasal  or pharyngeal samples from the 2007/2008 inﬂuenza sea-
on were provided by a clinical diagnostic laboratory located in
tuttgart, Germany. These samples from patients with acute res-
iratory tract infections were obtained by physicians mainly from
outhern Germany and were sent to the diagnostic laboratory in
iquid virus transport medium. Aliquots of the clinical specimens
with a laboratory number as an anonymous identiﬁer) were sent
o Novartis Vaccines in Marburg, Germany, by a weekly courier
ervice. During transportation the samples were stored at 2–8 ◦C.
irectly after receipt of the samples, MDCK 33016PF cells were
noculated (details see further below) with sample material. The
ultures were harvested after 3 days of incubation, and the cell-free
upernatants were aliquoted and stored at ≤−60 ◦C until further
se.
.2. Cell cultures and virus passaging
MDCK 33016PF suspension cells from Novartis working cell
ank were cultivated in 500 ml  disposable spinner ﬂasks (Corn-
ng) in CDM medium, a chemically deﬁned growth medium used
or cell propagation (MDCK 33016 CDM, Lonza) and passaged at
–4-day intervals. During those 3–4 days the cells grew from an
nitial seeding density of 1 × 105 cells/ml to densities between 1.0
nd 1.5 × 106 cells/ml. For infections 4.5 ml  cells were seeded in
0 ml  ﬁlter tubes (TPP, Transadingen, Switzerland) at a cell den-
ity of 0.8–1.2 × 106 cells/ml. Cells in CDM medium were diluted
t a 30/70% ratio into MDCK 33016 PFM medium (“protein-free
edium”, Gibco Invitrogen) supplemented with 0.5% of a peni-
illin/streptomycin solution (Sigma) and 900 IU/ml trypsin. To
btain a total culture volume of 5 ml,  the added viral inoculum
as diluted in 0.5 ml  infection medium and was pre-diluted by
everal log10 steps, starting with a total dilution of at least 1:100.
noculated cultures were then incubated at 33 ◦C for 3 days in a
% CO2 atmosphere in a ISF-1-W shaker incubator (Kuhner, Birs-
elden, Switzerland). For virus harvests the cells were separated by
entrifugation (800–1000 × g for 10 min) and the supernatant was
ecovered. Unless used freshly, e.g. for haemagglutination tests and
ubsequent passaging, aliquots of the supernatant were frozen at
−60 ◦C.
Haemagglutination (HA) testing was done with harvested mate-
ial to deﬁne the starting material for the next passage. HA testing
as performed in U-bottom microwell plates (Greiner Bio-One)
sing 100 l of a serial log2 dilution in PBS (pH 7.0) of the test
amples and 100 l chicken or guinea pig red blood cells (0.5%
n PBS pH 7.0). Results were read after 60 min  (chicken erythro-
ytes) or 120 min  (guinea pig erythrocytes) incubation at ambientAdenovirus type 4 Hexon
temperature within a temperature range of 19–25 ◦C. Two different
kinds of red blood cells were used since the actual H3N2 inﬂuenza
strains did not react with chicken red blood cells. Material from the
highest log10 inoculum dilution, which showed a clearly positive
HA reaction after the previous passage, was  used for the following
passage.
2.3. Multiplex PCR
Extraction  of viral DNA or RNA from clinical specimens and cul-
ture supernatants was performed with the Nucleic Acid Isolation
Kit I in the MagNA Pure compact extraction system (Roche) or
with the QIAsymphony® Virus/Bacteria Midi Kit (Qiagen) in the
QIAsymphony robotic system.
The ResPlex II v2.0 multiplex PCR panel (Qiagen) was used
according to the manufacturer’s instructions. The test applies a
RT-PCR (reverse transcription and PCR reaction) by the OneStep
RT PCR Kit (Qiagen) in combination with two pairs of speciﬁc
primers for each target. The enzyme mix contains the OmniscriptTM
and SensiscriptTM reverse transcriptase and the HotStarTaqTM
DNA polymerase. The dNTP mix  contained 10 mM of each dNTP.
The primer mix  consisted of a mixture of individual primers
for each viral target, carrying a tail with the target sequence
for the superprimers, and the forward and backwards super-
primers.
Results of the multiplex PCRs were read with the LiquiChip
detection system, which consists of microspheres coated with
target-speciﬁc hybridization molecules and a steptavidin–biotin
based ﬂuorescence detection reaction giving an individual ﬂuo-
rescence color pattern for each viral target. Result readings were
evaluated with the QIAplex MDD-RVO Beta software. According to
the manufacturer’s instructions signals above values of 150 are pos-
itive, values below 100 are negative and values between 100 and
150 are considered as questionable results. The method’s results
are given as counts (median ﬂuorescence intensity, MFI) but the
method is not intended or designed to be used quantitatively.
The  ResPlex II v2.0 method is designed to detect 18 different
virus species or virus subgroups simultaneously. These pathogens
and the target genes used are summarized in Table 1.
Independent, conventional in-house qRT-PCRs or commercially
available PCR methods were used to conﬁrm ResPlex results with
clinical specimens. These methods and according references are
summarized in Table 5.
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Table  2
Number and distribution of virus positive results in human samples collected during
the inﬂuenza season in spring 2008.
Virus Positive results Percentage
Inﬂuenza A 165 42.0%
Inﬂuenza B 152  38.7%
Adenovirus 6 1.5%
Bocavirus 2 0.5%
Coronavirus 13 3.3%
Enterovirus 22 5.6%
HMPV 4 1.0%
Parainﬂuenza virus 3 0.8%
Rhinovirus 16 4.1%
RSV 10 2.5%
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simian virus 40 (SV-40), budgerigar ﬂedgling disease polyomavirus,Total 393 100.0%
. Results
The total number of samples investigated was 468. Positive
esults with the ResPlex II v2.0 PCR were obtained with 370 (79%)
amples. Due to 21 double and one triple infection in the same
ample the total number of virus-positive results was  393 in the
70 samples. Of the positive results 317 (85.7%) were positive for
nﬂuenza virus with an almost equal distribution between A and B
ubtypes. 76 positive results with 66 samples indicated the pres-
nce of other respiratory viruses. The proportion of the different
iruses found by the multiplex PCR is shown in Table 2.
Of  particular interest were those specimens in which a dou-
le infection of an inﬂuenza virus together with other viruses was
etected. In 13 samples 14 positive (and 2 questionable) results
or other viruses were found associated with inﬂuenza virus. These
ssociated viruses are listed below along with extra remarks about
 samples that gave questionable results (100–150 MFI).
Adenovirus B and E – 2 samples.
Bocavirus  – 1 sample (plus 1 questionable bocavirus result in
another  sample).
Coronavirus NL 63, OC43, HKU1 – 5 samples (plus 1 questionable
coronavirus 229E in a sample found positive for inﬂuenza and
enterovirus).
Enterovirus  – 3 samples (1 of which was positive for inﬂuenza-,
entero-, and rhinovirus).
Rhinovirus  – 3 samples (1 of which was positive for inﬂuenza-,
entero-, and rhinovirus).
These samples were passaged up to ﬁve times in MDCK 33016
F cell as described in Section 2. In addition, sample 750 (compare
able 3) was also used for these passages, as it was questionably
ositive for bocavirus and contained inﬂuenza B. One other sam-
le (sample 670, positive for coronavirus HKU1 in association with
nﬂuenza virus B in the clinical specimen) could not be cultivated
ecause there was not sufﬁcient material.
As shown in Table 3, the only virus that was detectable after 2 (or
) passages was inﬂuenza virus; the other contaminating viruses
ere lost during passage. The table also lists the total dilution of the
riginal sample until passage 2 (10−7 to 10−9) and passage 5 (10−22
o 10−28). Only one sample (see sample 608 in Table 3), in which no
irus could be recovered was passaged at lower dilutions. The order
n which the detected viruses are listed in Table 3 reﬂects the counts
ound in the ResPlex method. Most co-infecting viruses had lower
ounts than the inﬂuenza virus. Sample 635 had highest counts for
n enterovirus and similar counts for rhinovirus and inﬂuenza virus,
ample 608 had higher counts for adenovirus than for inﬂuenza
irus. However, it should be noted that the ResPlex method is not
 quantitative method. (2012) 517– 522 519
In a similar way, samples with positive and questionable mul-
tiplex PCR results only for viruses other than inﬂuenza virus were
also cultivated for 2 or 3 passages in MDCK 33016PF cells. As shown
in Table 4, only two passages usually were sufﬁcient to eliminate
the virus, so that almost all samples tested negative. Only three
of the 54 viruses detected in the original sample still gave a very
weak Resplex signal after the second cell culture passage: one coro-
navirus with a signal just above the questionable level and an
enterovirus and one RSV at the questionable level. Considering the
total dilution from the original sample to the second passage of
only 2 × 104, it is possible that the original sample contained more
than 104 viruses and remained (weakly) positive during 2 passages
without any virus growth. When tested after the third culture pas-
sage (representing a 1:10 dilution of the clinical sample, these three
samples tested negative by Resplex II, indicating no virus growth
and that the weakly positive test results from the 2nd passage were
obviously due to residual virus from the original clinical sample.
Table  5 shows the results of conﬁrmatory test of clinical speci-
mens using independent, conventional PCR methods.
4.  Discussion
Inﬂuenza virus reference seeds are produced by WHO  on an
annual basis to match drifting inﬂuenza strains [19]. Reference
viruses are released to vaccine manufacturers after the WHO  rec-
ommendations have been published. These viruses are not subject
to any speciﬁc testing for adventitious viruses. The correspond-
ing vaccine must be manufactured, tested and distributed within
only a few months in order to meet vaccination schedules [20–22].
Because of this short timeline, conventional broad spectrum test-
ing of the inﬂuenza virus seed for adventitious agents cannot be
performed in time, particularly if one considers that months may
be needed to prepare virus from an independent source and spe-
ciﬁc antibodies against the same to neutralise the inﬂuenza virus.
For conventional egg-derived viral seeds it is commonly assumed
and supported by historical safety records, that many adventi-
tious viruses are removed by egg passages. Because cell-derived
inﬂuenza virus isolates are now being considered for use as starting
material for vaccine manufacture, information is needed about the
behaviour of adventitious viruses during cultivation of inﬂuenza
viruses in suitable cell substrates. Our studies contribute such
information for a cell line that is qualiﬁed for inﬂuenza vaccine
manufacture.
The result presented here should be seen in context with specif-
ically designed growth studies with a wide range of potentially
contaminating viruses, which, along with the results of a system-
atic literature search on growth of viruses in MDCK cells, have been
published previously, [8,9]. In those studies a standard amount of
106 infectious units (TCID50) per 100 ml  culture was  inoculated
into MDCK 33016 cells and the cells were grown for at least 14 days
(21 days for slow-growing viruses) in CDM growth medium. High
dilution passaging was  avoided but samples of suspended cells and
medium were taken at regular intervals to be tested for the virus,
and an adequate amount of fresh medium was  added after sampling
to maintain cell growth. The agents studied included: three human
adenovirus (types 1, 5, 6), herpes simplex virus (HSV), Epstein–Barr
virus, cytomegalovirus, parainﬂuenzavirus 3 and SV-5, respiratory
syncytial virus (RSV) type A and B, human coronavirus 229E, human
enterovirus species (Coxsackie A16, Coxsackie B30, Echovirus 6,
poliovirus type 1), two human metapneumo virus strains, three
different rhinoviruses, mammalian reovirus-3, BK polyomavirus,avian C-type retrovirus (Rous sarcoma virus), avian infectious bur-
sal disease birnavirus, two avian reovirus strains, minute virus of
mice (MVM)  parvovirus and porcine circovirus. Furthermore, the
520 B.  Roth et al. / Vaccine 30 (2012) 517– 522
Table  3
MDCK passages of ﬁeld samples positive for inﬂuenza virus plus other viruses.
Sample no. Original clinical sample 2nd passage MDCK 33016PF 5th passage MDCK 33016PF
Viruses detected Virus detected Total sample
dilution
Virus  detected Total sample
dilution
500 Inﬂuenza A, Enterovirus Inﬂuenza A 10−8 Inﬂuenza A 10−27
521 Inﬂuenza A Adenovirus B Inﬂuenza A 10−9 nd –
533  Inﬂuenza A, Bocavirus Inﬂuenza A 10−9 Inﬂuenza A 10−24
559 Inﬂuenza A, Enterovirus (Corona 229E)a Inﬂuenza A 10−9 Inﬂuenza A 10−25
565 Inﬂuenza B (Corona NL 63)a Inﬂuenza B 10−7 Inﬂuenza B 10−22
608 Adenovirus E, Inﬂuenza A none 10−4 nd –
621  Inﬂuenza B, Corona NL 63 Inﬂuenza B 10−9 Inﬂuenza B 10−26
635 Enterovirus, Inﬂuenza A, Rhinovirus Inﬂuenza A 10−9 Inﬂuenza A 10−23
639 Inﬂuenza A, Corona OC43 Inﬂuenza A 10−9 Inﬂuenza A 10−26
664 Inﬂuenza A, Rhinovirus Inﬂuenza A 10−9 Inﬂuenza A 10−25
721 Inﬂuenza A, Rhinovirus Inﬂuenza A 10−9 Inﬂuenza A 10−24
750 Inﬂuenza B (Bocavirus)a Inﬂuenza B 10−4 Inﬂuenza B 10−13
818 Inﬂuenza B, Corona HKU1 Inﬂuenza B 10−9 Inﬂuenza B 10−28
nd: not done.
a Questionable result placed in brackets.
Table 4
MDCK 33016PF passages of ﬁeld samples tested positive or questionable for respiratory tract viruses.
Viruses detected (no. of samples)
Original clinical sample 2nd passage MDCK 33016PF 3rd passage MDCK 33016PF
Enterovirus (16) None (15), Enterovirus (1, questionable) None (16)
Rhinovirus (12) None (12) nt
Coronavirus (9) None (8), Coronavirus (1, borderline) None (9)
Resp. Syncytial Virus (8) None (7), RSV (1, questionable) None (8)
Adenovirus (3) None (3) nt
Human metapneumovirus (3) None (3) nt
Parainﬂuenza virus (2) None (2) nt
Bocavirus  (1) None (1) nt
Three double infections were counted individually. Maximum dilution of the original specimen for the 2nd passages was 2 × 104 3rd passage was  done 1:10 from 2nd passage
supernatant. nt: not tested.
Table  5
Conﬁrmatory tests using independent, conventional PCR methods.
Target virus PCR method [Reference] ResPlex results
conﬁrmed
Remark
Inﬂuenzavirus [10] 317/317
Adenovirus Euroclone Duplic Real-time Adenovirus Kit 6/6
RSV A, B [11,12] 10/10
Enterovirus Artus® Enterovirus LC RT-PCR Kit version 2 [13] 9/22 Conserved 5′ UTR regions used for the
ResPlex method are shared by both
virus groups
Rhinovirus  [14,15] 11/16
Parainﬂuenza virus 3 Novartis Vaccines & Diagnostics in-house realtime
RT-PCR
0/3 From one sample no material was  left
for conﬁrmatory test
Coronavirus NL 63 [16] 5/5 Includes one questionable ResPlex
result (sample 656 in Table 3)
Coronavirus OC 43 [16] 1/1
Cornavirus 229E [16] 4/5 Includes one questionable ResPlex
result (sample 559 in Table 3)
Coronavirus HKU1 [16] 3/3
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hMPV [18] 
rowth of Mycoplasma hyorhinis and Chlamydia trachomatis were
ssessed. In those studies high virus growth was observed for
arainﬂuenzavirus 3, SV5 and herpes simplex virus, slow growth
as seen with mammalian reovirus 3, and questionable results
very low or no growth) were noted for the two avian reovirus. No
rowth was observed for the other viruses and agents tested. Infec-
ious titers declined and were in most cases no longer detectable
fter 3–5 days of cultivation. Only for few very stable viruses, such
s SV-40, virus titers persited longer.
Based upon those studies, and supported by the results of a
ystematic literature search (applicable to standard adherently3/3 Includes one questionable ResPlex
result (sample 750 in Table 3)
3/3
growing  MDCK cells), MDCK 33016 suspension cells support the
growth of only a limited range of viruses. In this context the rele-
vant viruses are inﬂuenza virus, parainﬂuenza virus, reovirus, and
herpes simplex virus. This permissiveness spectrum is very similar
to that seen in embryonated eggs [7]. Therefore, like embryonated
eggs used in current inﬂuenza vaccine manufacture, MDCK 33016
cells should act as an effective barrier for a wide range of adven-
titious agents. Moreover, MDCK 33016 cells do not support the
replication of many avian viruses. This is of particular relevance if
an avian virus contaminant is introduced into the process by prior
passaging of the vaccine virus strain in embryonated eggs.
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The clinical specimens used for our studies were collected dur-
ng the peak of an inﬂuenza season in February and March 2008
n order to gain more information about isolation rates in MDCK
3016PF cells in suspension culture. The results of those studies will
e published elsewhere. Considering the selection of specimens,
he high percentage of inﬂuenza-positive results is not surprising,
ut a signiﬁcant number of samples (66/370 or 17.8%) also tested
ositive for other viruses, such as adenovirus, bocavirus, corona-
irus, enterovirus, metapneumovirus (HMPV), parainﬂuenza virus
PIV), rhinovirus, and respiratory syncytial virus (RSV). Except for
SV and PIV, the same viruses were also detected as co-infections
ogether with inﬂuenza virus. Such co-infections together with
nﬂuenza viruses have also been published previously for RSV
23–25], PIV [23], HMPV [25,26], and for adenovirus and bocavirus
24], although the overall frequency was comparatively low. Those
revious reports were all based on PCR detection methods, apply-
ng a more restricted virus spectrum than the ResPlex II method.
e were unable to ﬁnd reports about co-infections of inﬂuenza
irus with other viruses identiﬁed via cell culture isolation meth-
ds, although such double-infected study materials have certainly
een used in high numbers. This indicates that cell cultures selec-
ively support replication of speciﬁc viruses and that, in addition,
he virus identiﬁcation methods used were less speciﬁc or less sen-
itive than PCR-based methods.
For the purpose of our studies the ResPlex II® multiplex PCR
ethod was chosen because it combined detection of a wide range
f relevant respiratory viruses with simple application (one-tube
ssay, rapid results from only one test run), and particularly because
t could be applied to the available small volumes. Currently, lim-
ted information is available about the sensitivity and speciﬁcity of
he ResPlex II v 2.0 test kit. We  have compared the novel ResPlex
II assay and existing techniques for the detection and subtyping
f inﬂuenza virus during the inﬂuenza season 2006–2007 [27].
he methodology must necessarily make some compromises, for
xample, with regard to ampliﬁcation conditions during the ﬁrst
ycles with speciﬁc primers. Thus it is not expected that sensitiv-
ty will be the same as that of monoplex PCRs. When compared to
n in-house quantitative real-time PCR for inﬂuenza virus (detec-
ion limit 1–10 TCID50/ml  of a fresh inﬂuenza virus harvest), the
esPlexII v2.0 test appeared to be about 1 log10 step less sensi-
ive.
The majority of positive results obtained with the ResPlexII v2.0
est could be conﬁrmed by other, independent conventional pub-
ished, in-house qRT-PCRs or commercially available PCR methods
hich used other target regions of the viral genomes. This applies
o all 317 inﬂuenza positive samples, 10 of 10 RSV A and B pos-
tive samples tested, 6 of 6 adenovirus positive samples, 3 of 3
ocavirus positive samples (including one questionable ResPlex
esult), and 13 of 14 positive coronavirus samples (including 2
uestionable ResPlex results). Differences were found for 2 parain-
uenza virus 3 samples, for which ResPlex results could not be
onﬁrmed; likewise only 11 of 16 rhinovirus samples and 9 of 22
nterovirus samples tested negative in independent PCRs, but were
ositive with the ResPlex method. It remains to be determined
hether the observed discrepancies are weaknesses of the ResPlex
ystem or of the other, independent PCRs. However, the manufac-
urer of the ResPlex method conﬁrmed certain cross-reactivities
etween enteroviruses and rhinoviruses, which have conserved 5′
TR regions that were used as targets for the PCR primers. Since it is
nown that reovirus may  grow in MDCK cells [9], we  also screened
any samples with an in-house reovirus qRT-PCR speciﬁc for mam-
alian orthoreovirus 1-3 (conserved region of the L3 inner capsid
ene). Samples in which no other virus was detected by the ResPlex
ethod were preferably used for the reovirus PCR. No reovirus was
ound in 271 of the specimens for which sufﬁcient material was still
vailable. (2012) 517– 522 521
Whereas the speciﬁc virus growth studies summarized and dis-
cussed further above applied cell-culture adapted virus strains,
the studies reported here used unadapted ﬁeld virus strains and
technical conditions as applied for inﬂuenza virus isolation and pas-
saging. These studies conﬁrmed that isolating inﬂuenza viruses in
MDCK 33016PF cells effectively reduced co-infecting viruses. After
only two passages and a 10−7 to 10−9 total dilution of the orig-
inal specimen, adeno-, boca-, corona-, entero-, and rhinoviruses
were no longer detectable. Only inﬂuenza viruses were recovered
and remained the only detectable virus upon further passage. High
dilutions of the inocula and short incubation periods of only 3 days
until harvest or the next passage are conditions that are normally
applied to effectively grow inﬂuenza viruses. These conditions cer-
tainly contributed to the rapid loss of the contaminating viruses.
Only viruses that are present at very high titers and which grow
very rapidly without adaptation would be able to survive such pas-
saging.
In a second series of passages we  also monitored more than
50 specimens that did not contain an inﬂuenza virus but were
positive for other respiratory viruses. In these specimens inter-
ference by competing inﬂuenza virus growth was excluded. The
culture conditions differed, as lower inoculum dilutions were used.
Each sample/harvest was diluted 1:100 into the culture, which is
the lowest standard dilution applied to recover very low-titred
inﬂuenza virus. Also under these conditions 54 positive results
for 8 different viruses became negative after only 2 or 3 pas-
sages and after a total dilution of the original specimen by a factor
of 2 × 10−4 to 2 × 10−5. When similar passages were conducted
with adherent Vero cells (“Vero WHO  seed”), several positive sam-
ples (adenovirus, rhinovirus, enterovirus, metapneumovirus, and
bocavirus) remained positive after 2 passages. However, except
for adenovirus, the counts did not increase but dropped (data not
shown).
These results demonstrate that, under practical conditions as
applied to grow inﬂuenza viruses, contaminating viruses can be
effectively removed by passaging in MDCK 33016PF cells. In com-
bination with their superior isolation efﬁciency [7,28], MDCK cells
appear highly suitable to be used as an alternative to embryonated
eggs to isolate and propagate candidate vaccine viruses.
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